Key result
Insulin therapy shows no link to severe CAD in T2DM, unlike insulin resistance markers.
Why the study?
The effect of insulin therapy on CAD remains controversial, prompting an analysis of the association between insulin resistance and the morbidity of severe CAD in T2DM.
Does insulin therapy increase the risk of severe coronary artery disease in patients with type 2 diabetes mellitus aged ≥40 years?
Cross-Sectional (n=2,044)
Does insulin therapy increase the risk of severe coronary artery disease in patients with type 2 diabetes mellitus aged ≥40 years?
Effect estimate: OR 1.138
Absolute Event Rate: 56.85% vs 53.65%
p-value: p=0.310
Insulin resistance, indicated by high fasting C-peptide or high BMI, rather than insulin therapy itself, is associated with an increased risk of severe CAD in patients with type 2 diabetes.
Insulin therapy should not yet prompt CAD concern in T2DM; hypothesis-generating for insulin resistance markers in observational data.
Objectives.The effect of insulin therapy on coronary artery disease (CAD) remains controversial. This study aimed to analyze the association between insulin resistance and the morbidity of severe CAD in type 2 diabetes mellitus (T2DM). Methods. A total of 2044 T2DM patients aged ≥40 years were included in this cross-sectional observational study. Clinical information and laboratory results were collected from the medical records. Those who underwent percutaneous coronary intervention (PCI) were classified as severe CAD, while those who did not have a history of and were not suffering from CAD were classified as patients without CAD. Results. T2DM patients with severe CAD and without CAD had no significant differences in glycosylated hemoglobin A1c (8.55% ± 2.10% vs. 8.39% ± 1.77%, <a:math xmlns:a="http://www.w3.org/1998/Math/MathML" id="M1"> <a:mi>P</a:mi> <a:mo>=</a:mo> <a:mn>0.234</a:mn> </a:math> ). The proportion of insulin treatment was also similar between the two groups (56.85% vs. 53.65%, odds ratio = 1.138, <c:math xmlns:c="http://www.w3.org/1998/Math/MathML" id="M2"> <c:mi>P</c:mi> <c:mo>=</c:mo> <c:mn>0.310</c:mn> </c:math> ). In the patients without insulin treatment, the levels of fasting C peptide (FCP) correlated with severe CAD prevalence. FCP was categorized into 3 tertiles (<1.5 ng/mL, 1.5 ng/mL- 3 ng/mL, and ≥3 ng/mL), and the prevalence rates of severe CAD were 7.88%, 14.31%, and 18.28%, respectively ( <e:math xmlns:e="http://www.w3.org/1998/Math/MathML" id="M3"> <e:mi>P</e:mi> <e:mo><</e:mo> <e:mn>0.05</e:mn> </e:math> ). In the patients with insulin treatment, the body mass index (BMI) was the significant risk factor of severe CAD. The prevalence of severe CAD according to BMI tertiles (<24 kg/m2, 24 kg/m2–28 kg/m2, and ≥28 kg/m2) was 11.22%, 14.61%, and 24.62%, respectively ( <g:math xmlns:g="http://www.w3.org/1998/Math/MathML" id="M4"> <g:mi>P</g:mi> <g:mo><</g:mo> <g:mn>0.01</g:mn> </g:math> ). Conclusions. Our results showed that insulin resistance, rather than insulin therapy, increases the risk of severe CAD in T2DM patients with inadequate glycemic control. Non-insulin treated patients with high FCP and insulin-treated patients with high BMI are at higher risk of severe CAD.
No takes yet. Share an insight, caveat, or question.
Song et al. (2022) conducted a cross-sectional in Type 2 diabetes mellitus (T2DM) (n=2,044). Insulin therapy vs. No insulin therapy was evaluated on Severe CAD (defined as undergoing percutaneous coronary intervention) (OR 1.138, p=0.310). Insulin therapy was not significantly associated with severe CAD in T2DM patients (56.85% vs 53.65%, OR 1.138, P=0.310), whereas markers of insulin resistance like high fasting C-peptide and BMI were.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: